Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Thrombosis with thrombocytopenia syndrome (TTS)

7-minute read

Key facts

  • The AstraZeneca COVID-19 vaccine has been linked to a new, very rare blood-clotting condition called thrombosis with thrombocytopenia syndrome (TTS).
  • Although it is no longer available, the AstraZeneca vaccine has been in recent use in Australia.
  • Symptoms of TTS have occurred between 4 and 42 days after vaccination with the AstraZeneca vaccine.
  • Blood clots are common and not all types of blood clot that occur after vaccination will be linked to the vaccine.
  • TTS is diagnosed using blood tests and imaging scans — such as a CT scan.
  • Once identified, TTS can be treated effectively in hospital.

What is thrombosis with thrombocytopenia syndrome?

Thrombosis with thrombocytopenia syndrome (TTS) is a very rare, new and specific syndrome. It occurs when a person has blood clots (thrombosis) as well as low platelet counts (thrombocytopenia). It’s also referred to as ‘vaccine-induced immune thrombotic thrombocytopenia’ (VITT).

Thrombosis is the formation of a blood clot, which prevents blood flowing normally through the body.

Thrombocytopenia is a condition where there aren’t enough platelets in the blood. Platelets help the blood to clot (clump), which stops you from bleeding excessively (for example, if you cut yourself).

Because your blood can’t form clots, low platelets can lead to bleeding problems.

Thrombocytopenia can be caused by many things — including medications, cancer, some cancer treatments, pregnancy, infection, an enlarged spleen and in rare cases, an ingredient in tonic water called quinine. Sometimes the cause is not known. There may also be a genetic link.

How is TTS and blood clots linked to the AstraZeneca vaccine?

Thrombosis with thrombocytopenia syndrome is a very rare side effect of the AstraZeneca COVID-19 vaccine. The AstraZeneca COVID-19 vaccine is no longer available in Australia, but it was available until recently.

In Australia, symptoms of TTS have occurred between 4 and 42 days (most commonly 4 to 30 days) after vaccination with the AstraZeneca vaccine. The risk of TTS appears to be higher in people aged under 60 years of age.

The blood clots can occur in different parts of the body, such as the brain (called cerebral venous sinus thrombosis, or CVST) or in the abdomen (idiopathic splanchnic vein thrombosis).

The mechanism that causes TTS is not fully understood, but it is similar to heparin-induced thrombocytopenia (HIT), a rare reaction to a medication called heparin.

TTS is different from general clotting conditions such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

Researchers are still working to understand TTS. One theory is that, in rare cases in some people, the AstraZeneca vaccine might produce antibodies that react with platelets — making them ‘stick together’. (Antibodies are the proteins made by your immune system to fight off foreign substances.)

This can cause blood clots, which stops platelets (and blood) from circulating through the body.

It’s important to note that only a link has been established. The AstraZeneca vaccine has not been proven to cause TTS. Blood clots are common and not all types of blood clot that occur after vaccination will be linked to the vaccine.

What are the symptoms of thrombosis with thrombocytopenia syndrome?

You should seek medical attention immediately if, following vaccination, you have any of these symptoms:

Common and expected side effects of COVID-19 vaccines include fever, sore muscles, tiredness and headache. These usually start within 24 hours of vaccination and last for 1 to 2 days. These side effects shouldn’t worry you unless they’re severe or persistent.

BOOK YOUR VACCINATION — Use the Service Finder to book a COVID-19 vaccination.

Are there any conditions that increase your risk of TTS — such as a history of blood clots?

There are a few rare conditions that potentially increase the risk of TTS. These conditions are:

  • cerebral venous sinus thrombosis (a type of blood clot in the brain)
  • heparin-induced thrombocytopenia (a reaction to a medication called heparin)
  • idiopathic splanchnic thrombosis (a blood clot in abdominal veins)
  • antiphospholipid syndrome with thrombosis

TTS is different to these rare conditions. But because there are similarities between TTS and each of these conditions, as a precaution it's recommended that people with a history of any of these conditions have the Pfizer (COMIRNATY) vaccine. The Pfizer vaccine is not linked with TTS.

There is no evidence that people with a history of blood clots (other than those described above) are at an increased risk of TTS.

How is thrombosis with thrombocytopenia syndrome diagnosed and treated?

People with TTS are very unwell and need to go to hospital, where they can be treated effectively. If a clot in the brain is suspected — called cerebral venous sinus thrombosis (CVST) — patients will be referred to an emergency department for further investigation. They will be cared for by a medical specialist.

To diagnose TTS, health professionals will perform blood tests — including a D-dimer test. If the blood tests show that TTS is suspected or likely, a CT scan may be performed.

Specialists have already developed specific ways to treat TTS, including using anticoagulant (anti-clotting) medication — other than heparin — intravenous immunoglobulin (an infusion of antibodies into the person’s bloodstream) and prednisolone (a type of steroid).

Now that doctors know how to recognise and treat TTS early, the chance of survival is very good.

Resources and support

Resources in your language

Learn more here about the development and quality assurance of healthdirect content.

Last reviewed: September 2021

Back To Top

Need more information?

These trusted information partners have more on this topic.

Top results

Vaxzevria (AstraZeneca) vaccine and thrombosis with thrombocytopenia (TTS) | Australian Government Department of Health and Aged Care

Thrombosis with thrombocytopenia (TTS) is a rare syndrome that occurred in around 2 to 3 people per 100,000 who were vaccinated with AstraZeneca. AstraZeneca is no longer available in Australia from 21 March 2023.

Read more on Department of Health and Aged Care website

COVID-19 vaccines: Frequently asked questions | NCIRS

COVID-19 vaccines: Frequently asked questions COVID-19 Aboriginal and Torres Strait Islander immunisation Australian Immunisation Handbook AusVaxSafety Big data Clinical research COSSI COVID-19 NCIRS COVID-19 response COVID-19 vaccine development landscape COVID-19 vaccines: Frequently asked questions COVID-19 vaccination program in Australia Disease surveillance and epidemiology Education and training New South Wales Immunisation Specialist Service (NSWISS) Paediatric Active Enhanced Disease Surveillance (PAEDS) PHN Immunisation Support program Program evaluation Regional and global collaborations Research to inform policy Sharing Knowledge About Immunisation (SKAI) Serosurveillance Social science in immunisation Vaccine coverage Vaccine safety We have provided answers to some of the most frequently asked questions about COVID-19 vaccines

Read more on National Centre for Immunisation Research and Surveillance (NCIRS) website

Healthdirect 24hr 7 days a week hotline

24 hour health advice you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information and advice

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Victorian government logo Government of Western Australia, health department logo

Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and present.